Published in Exp Biol Med (Maywood) on November 01, 2005
Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke (2008) 1.64
RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION). J Exp Stroke Transl Med (2009) 1.49
Glucose metabolism in fish: a review. J Comp Physiol B (2012) 1.17
The effect of granulocyte-colony stimulating factor in global cerebral ischemia in rats. Brain Res (2007) 0.99
Uptake of 18F-labeled 6-fluoro-6-deoxy-D-glucose by skeletal muscle is responsive to insulin stimulation. J Nucl Med (2009) 0.96
α1-Acid glycoprotein decreases neutrophil migration and increases susceptibility to sepsis in diabetic mice. Diabetes (2012) 0.96
Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol (2011) 0.95
Fibroblast growth factors preserve blood-brain barrier integrity through RhoA inhibition after intracerebral hemorrhage in mice. Neurobiol Dis (2012) 0.92
Alpha-chloralose is a suitable anesthetic for chronic focal cerebral ischemia studies in the rat: a comparative study. Brain Res (2007) 0.91
High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice. Mamm Genome (2013) 0.90
The effects of handling and anesthetic agents on the stress response and carbohydrate metabolism in northern elephant seals. PLoS One (2012) 0.88
Non-terminal blood sampling techniques in guinea pigs. J Vis Exp (2014) 0.85
Isoflurane is an effective alternative to ketamine/xylazine/acepromazine as an anesthetic agent for the mouse electroretinogram. Doc Ophthalmol (2007) 0.84
Comparison of Physiological Parameters and Anaesthesia Specific Observations during Isoflurane, Ketamine-Xylazine or Medetomidine-Midazolam-Fentanyl Anaesthesia in Male Guinea Pigs. PLoS One (2016) 0.84
Targeting post-infarct inflammation by PET imaging: comparison of (68)Ga-citrate and (68)Ga-DOTATATE with (18)F-FDG in a mouse model. Eur J Nucl Med Mol Imaging (2014) 0.84
Intravital microscopy evaluation of angiogenesis and its effects on glucose sensor performance. J Biomed Mater Res A (2010) 0.84
Euthanasia by CO₂ inhalation affects potassium levels in mice. J Am Assoc Lab Anim Sci (2010) 0.83
Severe intestinal ischemia can trigger cardiovascular collapse and sudden death via a parasympathetic mechanism. Shock (2011) 0.81
Comparison of anesthesia protocols for intravenous glucose tolerance testing in rhesus monkeys. J Med Primatol (2014) 0.81
Glucose-sensing pulmonary delivery of human insulin to the systemic circulation of rats. Int J Nanomedicine (2007) 0.81
Strategies for therapeutic hypometabothermia. J Exp Stroke Transl Med (2012) 0.81
Nasal absorption of mixtures of fast-acting and long-acting insulins. Int J Pharm (2010) 0.80
Modeling intracerebral hemorrhage in mice: injection of autologous blood or bacterial collagenase. J Vis Exp (2012) 0.80
A modified suture technique produces consistent cerebral infarction in rats. Brain Res (2008) 0.80
Efficacy and safety of five injectable anesthetic regimens for chronic blood collection from the anterior vena cava of Guinea pigs. J Am Assoc Lab Anim Sci (2008) 0.79
Xylazine-induced reduction of tissue sensitivity to insulin leads to acute hyperglycemia in diabetic and normoglycemic monkeys. BMC Anesthesiol (2013) 0.78
Comparison of the effects of three different combinations of general anesthetics on the electroretinogram of dogs. Doc Ophthalmol (2009) 0.78
Physiological, pharmacokinetic and liver metabolism comparisons between 3-, 6-, 12- and 18-month-old male Sprague Dawley rats under ketamine-xylazine anesthesia. Exp Anim (2015) 0.78
FDG-PET imaging for the evaluation of antiglioma agents in a rat model. Neuro Oncol (2008) 0.77
Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. J Control Release (2015) 0.77
PGC-1α expression is increased in leukocytes in experimental acute pancreatitis. Inflammation (2014) 0.77
Time-course of hypothalamic-pituitary-adrenal axis activity and inflammation in juvenile rat brain after cranial irradiation. Cell Mol Neurobiol (2012) 0.77
The Effects of Physiological and Methodological Determinants on 18F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model. Mol Imaging (2016) 0.77
Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract (2015) 0.77
Effect of anesthetics on gastric damage using two models of portal hypertension. World J Gastrointest Pharmacol Ther (2010) 0.77
Abscisic Acid Stimulates Glucagon-Like Peptide-1 Secretion from L-Cells and Its Oral Administration Increases Plasma Glucagon-Like Peptide-1 Levels in Rats. PLoS One (2015) 0.76
Chromium supplementation improves glucose tolerance in diabetic Goto-Kakizaki rats. IUBMB Life (2008) 0.75
Acute hyperglycemia suppresses left ventricular diastolic function and inhibits autophagic flux in mice under prohypertrophic stimulation. Cardiovasc Diabetol (2016) 0.75
Blood biochemical changes in mice after administration of a mixture of three anesthetic agents. J Vet Med Sci (2016) 0.75
Use of anesthesia dramatically alters the oral glucose tolerance and insulin secretion in C57Bl/6 mice. Physiol Rep (2016) 0.75
The metabolic syndrome induces early changes in the swine renal medullary mitochondria. Transl Res (2017) 0.75
Biochemical Effects of Xylazine, Propofol, and Ketamine in West African Dwarf Goats. J Vet Med (2014) 0.75
Long-term in vivo polychlorinated biphenyl 126 exposure induces oxidative stress and alters proteomic profile on islets of Langerhans. Sci Rep (2016) 0.75
An anesthetic method compatible with (18)F-FDG-PET studies in mice. Am J Nucl Med Mol Imaging (2015) 0.75
Acute exercise boosts cell proliferation and the heat shock response in lymphocytes: correlation with cytokine production and extracellular-to-intracellular HSP70 ratio. Cell Stress Chaperones (2017) 0.75
Cardiac Radionuclide Imaging in Rodents: A Review of Methods, Results, and Factors at Play. Front Med (Lausanne) (2017) 0.75
Nanoparticle Delivered Human Biliverdin Reductase-Based Peptide Increases Glucose Uptake by Activating IRK/Akt/GSK3 Axis: The Peptide Is Effective in the Cell and Wild-Type and Diabetic Ob/Ob Mice. J Diabetes Res (2016) 0.75
Does stress-induced release of interleukin-1 cause liver injury? Cell Mol Neurobiol (2012) 0.75
Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res (2004) 3.30
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J (2006) 3.10
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med (2015) 2.03
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol (2008) 1.83
Tissue structure and connexin expression of canine pulmonary veins. Cardiovasc Res (2002) 1.77
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy (2008) 1.77
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J (2007) 1.73
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol (2010) 1.66
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol (2013) 1.65
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J (2007) 1.61
Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med (2004) 1.57
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost (2012) 1.42
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med (2013) 1.32
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost (2005) 1.25
Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness. J Surg Res (2004) 1.13
IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease. J Immunol (2009) 1.07
Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen. J Infect Dis (2005) 1.06
Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. Immunology (2003) 1.03
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J (2009) 1.03
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther (2010) 0.97
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol (2007) 0.97
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol (2009) 0.97
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost (2008) 0.95
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol (2013) 0.93
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets (2006) 0.93
Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks. Anticancer Res (2011) 0.92
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J Am Coll Cardiol (2012) 0.91
Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. Haematologica (2012) 0.90
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol (2013) 0.90
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol (2007) 0.90
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol (2012) 0.90
Effects of hyperglycemia and insulin therapy on outcome in a hyperglycemic septic model of critical illness. J Trauma (2006) 0.88
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets (2008) 0.88
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J (2009) 0.87
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets (2009) 0.86
Clopidogrel poor responders: an objective definition based on Bayesian classification. Platelets (2007) 0.86
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost (2005) 0.86
The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel. Biochem Pharmacol (2007) 0.85
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets (2006) 0.84
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol (2012) 0.84
Platelet activation and inhibition in sickle cell disease (pains) study. Platelets (2013) 0.83
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost (2002) 0.83
A model of controlled acute hyperglycemia in rats: Effects of insulin and glucagon-like peptide-1 analog. J Pharmacol Exp Ther (2005) 0.82
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost (2007) 0.82
Absence of "rebound" platelet hyperreactivity following cessation of prasugrel. Thromb Haemost (2011) 0.81
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther (2007) 0.81
Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. J Thromb Haemost (2008) 0.81
Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol (2010) 0.81
P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc (2013) 0.81
Biomarkers of exocrine pancreatic injury in 2 rat acute pancreatitis models. Toxicol Pathol (2013) 0.81
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost (2011) 0.80
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets (2008) 0.80
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet (2010) 0.80
Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occlusive diseases. Eur J Pharmacol (2009) 0.79
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Eur J Pharmacol (2007) 0.79
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thromb Haemost (2013) 0.79
Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats. J Cardiovasc Pharmacol (2011) 0.79
Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. Platelets (2011) 0.78
FoxA2 involvement in suppression of protein C, an outcome predictor in experimental sepsis. Clin Vaccine Immunol (2006) 0.78
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol (2015) 0.78
Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost (2010) 0.78
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets (2012) 0.78
Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? Thromb Haemost (2012) 0.77
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. J Cardiovasc Pharmacol (2011) 0.77
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thromb Haemost (2014) 0.77
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. J Thromb Thrombolysis (2014) 0.76
Activated protein C modulates chemokine response and tissue injury in experimental sepsis. Adv Exp Med Biol (2008) 0.76
Beyond platelet functional testing: value in the aggregate. Biomark Med (2011) 0.76
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent. Int J Toxicol (2012) 0.76
Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation. Thromb Haemost (2013) 0.76
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention. J Am Coll Cardiol (2015) 0.75
In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. Thromb Res (2013) 0.75
Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus. Thromb Haemost (2016) 0.75
Ethanol enhances the inhibitory effect of an oral GPIIb/IIIa antagonist on human platelet function. J Lab Clin Med (2002) 0.75
Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting. Hosp Pract (1995) (2014) 0.75
Study of plasma protein C and inflammatory pathways: biomarkers for dimethylnitrosamine-induced liver fibrosis in rats. Eur J Pharmacol (2007) 0.75